SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/D266401DF66509EAAA7A9E7D9B9CFEF08C96D957DFB1324B79397AE1754E45802850C0F0347741F4BDCE64D4441DFE68>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/D266401DF66509EAAA7A9E7D9B9CFEF08C96D957DFB1324B79397AE1754E45802850C0F0347741F4BDCE64D4441DFE68
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/D266401DF66509EAAA7A9E7D9B9CFEF08C96D957DFB1324B79397AE1754E45802850C0F0347741F4BDCE64D4441DFE68
http://www.w3.org/2000/01/rdf-schema#comment
"Several studies have demonstrated the absence of objective response in patients treated with irinotecan-cetuximab after failure of irinotecan when the tumour presents a KRAS mutation."
xsd:string
http://purl.uniprot.org/uniprot/#_15AE490C32A0DEB40DA485A242242BA0D908CD1667D79EFE1F8039A990051BABA0DA7B4CAFE6805C68BF5C89711C16BF
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/D266401DF66509EAAA7A9E7D9B9CFEF08C96D957DFB1324B79397AE1754E45802850C0F0347741F4BDCE64D4441DFE68
http://purl.uniprot.org/uniprot/A5HC25
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/D266401DF66509EAAA7A9E7D9B9CFEF08C96D957DFB1324B79397AE1754E45802850C0F0347741F4BDCE64D4441DFE68
http://purl.uniprot.org/uniprot/#_A5HC25-mappedCitation-19702696
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/D266401DF66509EAAA7A9E7D9B9CFEF08C96D957DFB1324B79397AE1754E45802850C0F0347741F4BDCE64D4441DFE68